Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vaccine Makers Weigh Benefits Of Seasonal Influenza Versus Swine Flu Via “Educated Guess”

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Even if all the necessary elements to make a swine flu vaccine are in place or to ramp up production of anti-viral drugs, multinational drug companies may see little upside in actually doing either

You may also be interested in...



Developing A Pandemic Vaccine Is A Race Against Time, Says IFPMA Director General

HONG KONG - Global vaccine makers are ready to mass-produce vaccines for H1N1 as soon as health authorities need, says the head of the global association that represents multinational vaccine makers

Developing A Pandemic Vaccine Is A Race Against Time, Says IFPMA Director General

HONG KONG - Global vaccine makers are ready to mass-produce vaccines for H1N1 as soon as health authorities need, says the head of the global association that represents multinational vaccine makers

China Produces Tamiflu And Relenza Locally To Prepare For Swine Flu

China's health and relevant authorities are gearing up to tackle the rapidly spreading swine flu. Besides stockpiling Roche's Tamiflu and GSK's Relenza, the country is producing the drugs locally. During the 2005 bird flu outbreak, Roche and GSK authorized Shanghai Pharmaceutical and Guangdong Oriental Sunshine Pharmaceuticals to manufacture their drugs, and Simcere to localize the production. With an annual output of 200 million Tamiflu tablets, Guangdong Oriental Sunshine has the largest production capability worldwide and has received purchase orders from provincial governments such as Guangdong, Hubei and Anhui. Shanghai Pharmaceutical said it will start production upon receiving orders. Meanwhile, Simcere is planning to ask China's State FDA to fast-track the approval for its clinical trial, which was suspended when the avian outbreak did not occur. (Click here for more - Chinese language)
UsernamePublicRestriction

Register

SC071599

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel